China's NDRC Rumored To Cut Prices Of Brand-Name Primary Chinese Medicines
This article was originally published in PharmAsia News
Executive Summary
China's National Development and Reform Commission is in discussions with provincial commodity price departments about cutting the prices of patent-protected essential Chinese drugs, such as Yunnan Baiyao, which constitute a large portion of drug makers' sales